CDKN2A and cancer: Thus, in ESCC patients subjected to CRT, the role of BMI1-mediated inhibition of p16INK4A protein is not clear, and the clinical effect of Hh signalling pathway activation might be more evident than that of the presence of BMI1, whilst BMI1and Gli-1 both play important roles in cancer progression.